Sorted By:

Relevance


Poll respondents appreciate economic benefits of innovation and call for more protections

PhRMA  |  Blog Post

When asked about which industries were perceived as most innovative, the technology industry is seen as the leader in innovation, followed by biopharma, agriculture and manufacturing.
http://catalyst.phrma.org/poll-respondents-appreciate-economic-benefits-of-innovation-and-call-for-more-protections

Innovative Biopharmaceutical Companies Seek to Improve R&D Efficiency

Chartpack  |  From Our Network

...
http://chartpack.phrma.org/2016-perspective/chapter-2/innovative-biopharmaceutical-companies-seek-to-improve-randd-efficiency

Innovative Biopharmaceutical Companies Seek to Improve R&D Efficiency

Chartpack  |  From Our Network

Biopharmaceutical companies are using new approaches to increase R&D efficiency and effectiveness....
http://chartpack.phrma.org/biophrma-chartpack/research-and-development/innovative-biopharmaceutical-companies-seek-to-improve-randd-efficiency

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

In fact, companies cited inability to measure and/or track such real-world outcomes as leading barriers to implementation of new approaches to paying for medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

Ask About Adherence: Q&A with PhRMA Foundation Young Investigator Adherence Grantee - Xian Shen

PhRMA  |  Blog Post

SHEN: With the support of the PhRMA Foundation grant, I am able to conduct cutting-edge research that will help to guide real-world solutions to adherence problems.
http://catalyst.phrma.org/ask-about-adherence-–-qa-with-phrma-foundation-young-investigator-adherence-grantee-xian-shen

Why reauthorization of PDUFA matters

PhRMA  |  Blog Post

As the Senate now considers this important legislation, here are a few resources to help better explain why PDUFA is good for patients:  Find out how PDUFA benefits patients and advances medical innovation in this fact sheet.
http://catalyst.phrma.org/why-reauthorization-of-pdufa-matters

State Leaders See Bioscience as Jobs Engine

PhRMA  |  Blog Post

In a nut shell, it talks about what is happening in Indiana where an alliance of business, labor and public policy leaders are working together to strengthen the bioscience sector in the state.
http://catalyst.phrma.org/state-leaders-see-bioscience-as-jobs-engine

PhRMA Applauds Korea-U.S. Free Trade Agreement Sent to Capitol Hill

PhRMA  |  Press Release

Washington, D.C. (October 3, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani released the following statement on the transmittal to the Congress of the Korea-U.S. Free Trade Agreement:   “PhRMA is pleased that t...
https://www.phrma.org/press-release/phrma-applauds-korea-u-s-free-trade-agreement-sent-to-capitol-hill

Who gets a seat at ICER’s table? Hint: It’s not patients

PhRMA  |  Blog Post

Learn more about how ICER’s methodology fails to meet patients’ needs here.
http://catalyst.phrma.org/who-gets-a-seat-at-icers-table-hint-its-not-patients

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines

PhRMA  |  Blog Post

MedPAC’s proposed changes would impede the competitive market through government price setting, including a restrictive binding arbitration process to set prices for new drugs.
http://catalyst.phrma.org/medicare-monday-new-report-highlights-progress-in-fighting-cancer-with-new-physician-administered-medicines

No Two Patients with High Cholesterol are the Same: Meet Sheryl and Bill

PhRMA  |  Blog Post

She is one of millions of Americans able to keep high cholesterol levels at bay with diet, exercise and statin therapy.
http://catalyst.phrma.org/no-two-patients-with-high-cholesterol-are-the-same-meet-sheryl-and-bill

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

In fact, companies cited inability to measure and/or track such real-world outcomes as leading barriers to implementation of new approaches to paying for medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

In fact, companies cited inability to measure and/or track such real-world outcomes as leading barriers to implementation of new approaches to paying for medicines.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

Nearly 300 Medicines in Development to Meet Unique Needs of Children

PhRMA  |  Press Release

PREA and BPCA are set to expire on October 1, 2012 unless reauthorized or made permanent by Congress.
https://www.phrma.org/press-release/nearly-300-medicines-in-development-to-meet-unique-needs-of-children

Rheumatoid Arthritis Quality: Current and Future Status

PhRMA  |  Fact Sheet

Download the fact sheet to learn more.
https://www.phrma.org

Members

PhRMA  |  From PhRMA

PhRMA member companies invest billions in the research and develop of new medicines. They are pioneers in innovation, ushering in a new era of treatment for patients. If your company is interested in joining PhRMA, cl...
https://www.phrma.org/about/members

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

PhRMA  |  Blog Post

As part of its effort to modernize NAFTA, the U.S. should seek to ensure stronger enforcement of patentability standards and the provisions that protect the IP of U.S. innovators, as well as address potentially negative price-setting measures.
http://catalyst.phrma.org/as-u.s.-looks-to-modernize-nafta-strong-enforcement-of-existing-obligations-should-be-a-top-priority

Schizophrenia Quality: Current and Future Status

PhRMA  |  Fact Sheet

Download the fact sheet to learn more.
https://www.phrma.org

Why drug importation threatens patient safety

PhRMA  |  Blog Post

In fact, the National Association of Boards of Pharmacy found that 96 percent of 10,000 online drug sellers were not in compliance with U.S. pharmacy laws and standards.
http://catalyst.phrma.org/why-drug-importation-threatens-patient-safety

340B

PhRMA  |  From PhRMA

For a printable version of this interactive timeline, click here.
https://www.phrma.org/advocacy/340b

Medicare Monday: Medicare Part D by the numbers

PhRMA  |  Blog Post

More than 700 plans: Nationwide, Part D beneficiaries have more than 700 prescription drug plans to choose from in 2017.
http://catalyst.phrma.org/medicare-monday-medicare-part-d-by-the-numbers

ICYMI: Wall Street Journal and Washington Post Say TPP Should Protect Medical Innovation

PhRMA  |  Blog Post

“ In closing, the Journal editors lay bare the deal’s importance in sharpening America’s competitive edge: “TPP…would be the first major trade deal to liberalize trade in services and include protections against commercial intellectual-property theft and official expropriation of assets.
http://catalyst.phrma.org/icymi-wsj-and-washington-post-say-tpp-should-protect-medical-innovation

Resources for understanding the dangers of drug importation

PhRMA  |  Blog Post

Many are concerned about the safety of drugs imported from other countries –our pocket card explains how importation schemes could harm patients.
http://catalyst.phrma.org/resources-for-understanding-the-dangers-of-drug-importation

Supporting opportunities for enhanced competition in the marketplace

PhRMA  |  Blog Post

REMS are necessary to ensure patient safety and cannot be used to delay generic competition The CREATES Act as proposed would give generic drug companies the ability to file lawsuits to obtain samples of drugs and conduct testing without safeguards equivalent to those required under risk evaluation and mitigation strategies (REMS) applicable to the innovator medicine. 
http://catalyst.phrma.org/supporting-opportunities-for-enhanced-competition-in-the-marketplace

A state-by-state look at coverage and access hurdles in 2016 exchange plans

PhRMA  |  Blog Post

Based on the data and information gathered, the fact sheets also include suggestions for improving exchange coverage in each state.
http://catalyst.phrma.org/a-state-by-state-look-at-coverage-and-access-hurdles-in-2016-exchange-plans

You have reviewed the first 175 results out of 1196. Each page contains 25 results. You're on page 7.

prev 7 8 9 10 11 12 next